Circulating tumour DNA (ctDNA) is emerging as an important tool that appears representative of the DNA and the overall tumour mutational landscape of a patient's disease state [7, 8] and, for patients with ER+, HER2− advanced breast cancer, has prognostic and predictive response value [6, 9, 10]. This evidence concerns the gene ESR1 and breast cancer.